The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide

Molecular Pharmacology

Volumn 67, Issue 1, 2005, Pages 15-19

  Lo Verme, Jesse ^a   Fu, Jin ^b   Astarita, Giuseppe ^b   La Rana, Giovanna ^c   Russo, Roberto ^c   Calignano, Antonio ^c   Piomelli, Daniele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 (1 CYCLOHEXANEBUTYL) 3 CYCLOHEXYLUREIDOETHYL]PHENYLTHIO] 2 METHYL PROPIONIC ACID; ANTIINFLAMMATORY AGENT; CARRAGEENAN; CELL NUCLEUS RECEPTOR; GW 7647; MESSENGER RNA; N OLEOYLETHANOLAMINE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHORBOL ESTER; PIRINIXIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OTITIS; PAW EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASE SEQUENCE; CARRAGEENAN; CROSSES, GENETIC; DNA PRIMERS; EDEMA; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PALMITIC ACIDS; POLYMERASE CHAIN REACTION; PPAR ALPHA; TETRADECANOYLPHORBOL ACETATE;

EID: 11244328917     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.006353     Document Type: Article

References (40)

1. Aloe L, Leon A, and Levi-Montalcini R (1993) A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39:C145-C147.
2. Bachur NR, Masek K, Melmon KL, and Udenfriend S (1965) Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem 240:1019-1024.
3. Benvenuti F, Lattanzi F, De Gori A, and Tarli P (1968) Attivita' di alcuni derivati della palmitoiletanolamide sull'edema da carragenina nella zampa di ratto. Boll Soc Ital Biol Sper 44:809-813.
4. Berdyshev E, Boichot E, Corbel M, Germain N, and Lagente V (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 63:PL125-PL129.
5. Berger J and Moller DE (2002) The mechanisms of action of PPAEs. Annu Rev Med 53:409-435.
6. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, and Willson TM (2001) Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett 11:1225-1227.
7. Cadas H, di Tomaso E and Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17:1226-1242.
8. Calignano A, La Rana G, Giuffrida A, and Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature (Lond) 394:277-281.
9. Calignano A, La Rana G, and Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191-198.
10. Chinetti G, Fruchart JC, and Staels B (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497-505.
11. Conti S, Costa B, Colleoni M, Parolaro D, and Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135:181-187.
12. Costa B, Conti S, Giagnoni G, and Colleoni M (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation; inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 137:413-420.
13. Cravatt BF and Lichtman AH (2002) The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121:135-148.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
15. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, and Wahli W (1996) The PPAR alpha-leukotriene B4 pathway to inflammation control. Nature (Land) 384:39-43.
16. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, and Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376-3380.
17. 2-like receptors. Pain 97:11-21.
18. Farquhar-Smith WP and Rice AS (2001) Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94:507-513.
19. Farquhar-Smith WP and Rice AS (2003) A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99:1391-1401.
20. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (Lond) 425:90-93.
21. Guzman M, Lo Verme J, Oveisi F, Blazquez C, and Piomelli D (2004) Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor PPAR-alpha. J Biol Chem 279:27849-27854.
22. Hansen HS, Lauritzen L, Moesgaard B, Strand AM, and Hansen HH (1998) Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity. Biochem Pharmacol 55:719-725.
23. Jaggar SI, Hasnie FS, Sellaturay S, and Rice AS (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189-199.
24. Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, and Fowler CJ (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the etidocannabinoid anandamide. Br J Pharmacol 133:1263-1275.
25. Kahlich R, Klima J, Cihla F, Frankova V, Masek K, Rosicky M, Matousek F, and Bruthans J (1979) Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 23:11-24.
26. Kuehl FA, Jacob TA, Ganley OH, Ormond RE, and Meisinger MAP (1957) The identification of N-(2-hydroxyethyl)-palmitaimde as a naturally occurring antiinflammatory agent. J Am Chem Soc 79:5577-5578.
27. Lambert D, Vandevoorde S, Jonsson K, and Fowler J (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9:663-674.
28. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, and Robert AR (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42:321-327.
29. Long D and Martin A (1956) Factors in arachis oil depressing sensitivity to tuberculin in BCG infected guinea pigs. Lancet 270:464-466.
30. Mandard S, Muller M, and Kersten S (2004) Peroxisome proliferator- activated receptor alpha target genes. Cell Mol Life Sci 61:393-416.
31. Mazzari S, Canella R, Petrelli L, Marcolongo G, and Leon A (1996) N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300:227-236.
32. Perlik F, Raskova H, and Elis J (1971) Anti-inflammatory properties of N(2-hydroxyethyl) palmitamide. Acta Physiol Acad Sci Hung 39:395-400.
33. Ren B, Thelen A, and Jump DB (1996) Peroxisome proliferator-activated receptor α inhibits hepatic S14 gene transcription. Evidence against the peroxisome proliferator-activated receptor a as the mediator of polyunsaturated fatty acid regulation of s14 gene transcription. J Biol Chem 271:17167-17173.
34. Rodriguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, et al. (2001) An anorexic lipid mediator regulated by feeding. Nature (Lond) 414:209-212.
35. Ross RA, Brockie HC, and Pertwee RG (2000) Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 401:121-130.
36. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, and Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665-672.
37. Schmid HH, Schmid PC, and Natarajan V ( 1996) The N-acylation- phosphodiesterase pathway and cell signalling. Chem Phys Lipids 80:133-142.
38. Sheu M, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr J, Man M, Elias P, and Feingold K (2002) Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Investig Dermatol 118:94-101.
39. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, and Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolaimne or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612.
40. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.